RECENT NEWS

Gyros Protein Technologies announced recently that Oxford BioMedica has invested in two Gyrolab xPlore systems. This is the first time the Gyrolab technology has been applied within the gene and cell therapy area.

The independent charity Coeliac UK has launched a research fund and accompanying fundraising appeal, which aims to raise £5 million to change the future for people with coeliac disease and gluten-related autoimmune conditions. It will boost research efforts into key areas identified and agreed by patients, carers and healthcare professionals.

Developed by scientists at the VIB University of Ghent, Belgium, the Glyco Liver Profile test from Helena Biosciences is the first of its kind delivering a comprehensive picture of chronic liver disease enabling clinicians to diagnose and monitor patients with hepatic inflammation, fibrosis and cirrhosis while providing a prognostic marker of hepatocellular carcinoma (HCC) risk.

In work recently undertaken and published as a case study by the Oxford Academic Health Science Network (AHSN), Horiba UK Medical’s Microsemi CRP point-of-care testing (POCT) analyser was found to enable more rapid clinical decision-making, saving time and reducing costs, in emergency paediatric units.

The sixth in this important series of articles by Stephen MacDonald on individual aspects of the assessment of uncertainty of measurement considers the impacts created when contributors are not measured in the same units. Coverage continues towards understanding the application of measurement uncertainty to laboratory assays.

Vector Laboratories has announced its new five-part video training series on immunohistochemistry (IHC). 'Become an IHC Expert (and Avoid Common Pitfalls)' is being released online, one segment per day. Access to the training series is free of charge, and topics covered include how to select reagents depending on experimental priorities, how to use ancillary reagents to improve results, how to optimise the protocol, and when to use advanced detection protocols.

Horizon Discovery has introduced Edit-R CRISPRa arrayed CRISPR RNA (crRNA) libraries, the latest addition to its CRISPR activation (CRISPRa) reagent platform from the recently acquired Dharmacon business. The new libraries offer a powerful tool for drug discovery, pathway analysis and disease progression studies.

Medical Research Council-funded scientists are beginning a five-year study of childhood arthritis and its linked eye inflammation, uveitis, with the aim of better understanding how to treat the complex condition, which affects one in 1000 under the age of 16 in the UK.

Driving down turnaround times (TATs), to enable more rapid diagnosis and treatment of patients, is the key philosophy of Source BioScience. As a leading provider of outsourced histopathology services to the NHS and private healthcare centres in the UK, Source BioScience has, after a detailed review of all other available alternatives in the digital marketplace, unveiled investment in a digital pathology platform from its preferred partner, Philips.

Approximately 41,000 people are diagnosed with colorectal cancer (CRC) in the UK each year, and over 90% of cases are treated successfully following early detection. Diagnosis of CRC is normally achieved by colonoscopy; however, UK endoscopy resources are stretched to breaking point.

Medical diagnostics manufacturer Helena Biosciences, working in collaboration with AB Scientific, has been awarded the Northern Ireland regional tender for the supply and delivery of clinical electrophoresis. Helena Biosciences is a manufacturer of medical diagnostics equipment used in clinical laboratories worldwide.

Melbourne-based Henley Health has been appointed as Intelligent Fingerprinting’s first Asia Pacific region distributor for its new non-invasive and flexible drug test solution. The world’s first portable fingerprint-based drug test – which works by analysing sweat from a fingerprint to determine if someone has recently used cocaine, opiates, amphetamines or cannabis – is now available in Australia and New Zealand following this agreement.

Autoscribe Informatics will be exhibiting for the first time at Analytica 2018.This will provide visitors with the chance to see the versatile and powerful Matrix Gemini laboratory I information management system (LIMS), which is supported through a network of distributors across mainland Europe. Characterised by its easy-to-use graphical configuration tools, and with a dual desktop/web interface included as standard, Matrix can be used to create LIMS solutions that meet the exact needs of customers.

A study recently undertaken and published by the Oxford Academic Health Science Network (AHSN) has shown that Horiba’s Microsemi CRP point-of-care testing (POCT) analyser facilitates more rapid clinical decision-making, saving time and reducing costs, in emergency paediatric units. The study found that using POCT as a replacement for laboratory tests resulted in earlier decision-making in approximately 75% of cases across three hospital sites. Economic analysis across these sites found that this could result in net annual cost savings due to reduced staff time, as well as faster decisions on antibiotic use.

Radiometer has implemented its AQURE Enterprise point-of-care (POC) data management system at the University of Leicester Hospitals NHS Trust’s new emergency department (ED). Radiometer has also provided support in configuring the interface of the trust’s Sunquest Integrated Clinical Environment (ICE) EPR system so that blood gas test results are automatically linked to an individual’s electronic patient record (EPR).

The British Society for Microbial Technology (BSMT) is offering an excellent programme for its annual scientific conference, to be held on Friday, 18 May 2018 in London. This year, the focus of the meeting will be on Rapid Diagnostics – Time is Relative. While aimed at bench microbiologists, the conference is relevant for senior biomedical and clinical scientists, other scientists and medical microbiologists.

A new study has found that a blood test for cancer DNA could predict if a woman is responding to the new breast cancer drug palbociclib, months earlier than current tests. Scientists from The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust, say the test could detect in two to three weeks whether or not the drug is working, although they caution that the results need replicating before they are used clinically.

Cherwell Laboratories has published an eBook entitled The Pharmaceutical and Cleanroom Industry’s Pocket Guide to Prepared Culture Media. Available to download from the company’s website, the new guide is intended for anyone involved in using and/or buying microbiological media. It aims to provide an understanding of the best practices and breadth of prepared culture media options for various applications.

Horiba UK Medical has announced that Thame and Marlow Community Hubs, within Buckinghamshire Healthcare NHS Trust, have each installed the company’s latest point-of-care testing (POCT) analyser, the Microsemi CRP. These new analysers are now streamlining existing diagnostic pathways in the community and helping to reduce local accident and emergency (A&E) admissions for frail patients.

Horizon Discovery Group has entered into an agreement with Roche Diagnostics to assist in the development of immunohistochemistry (IHC) assays. Under the terms of the agreement, Horizon will develop and provide reference standard material expressing neurotrophic tropomyosin receptor kinase (NTRK) fusion biomarkers.